Videos

The director of Geriatric Psychiatry at the St Louis University School of Medicine discussed the need to improve awareness of the signs of psychiatric-related symptoms and to eliminate the stigmas associated with them. [WATCH TIME: 3 minutes]

The Distinguished Professor Emerita at Indiana University School of Nursing spoke on the prevalence of stigma in the field of epilepsy and how it can affect the daily life of patients. [WATCH TIME: 4 minutes]

The vascular neurologist at Allegheny Health Network provided an overview of the RapidAI and how it is evolving the way clinicians manage and treat patients who present with stroke. [WATCH TIME: 4 minutes]

Alberto Ascherio, MD, DrPH, and Lawrence Steinman, MD, join NeurologyLive in a conversation about the clinical and research implications of a causative relationship between Epstein-Barr virus and multiple sclerosis.

The Samuel W. Fordyce professor and director of Geriatric Psychiatry at the St Louis University School of Medicine discussed the critical roles specialists and caregivers during telehealth visits in long-term care settings. [WATCH TIME: 4 minutes]

The assistant director of the Allegheny Headache Center provided insight on how the center utilizes its headache registry to construct treatment plans, along with identifying questions that still need answers. [WATCH TIME: 3 minutes]

The director of Geriatric Psychiatry at the St Louis University School of Medicine discussed what clinicians should pay attention to when conducting telehealth visits for psychosis-related symptoms in patients with neurodegenerative diseases. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending February 19, 2022. [WATCH TIME: 3 minutes]

The director of the Multiple Sclerosis and Neuromyelitis Optica Unit at Massachusetts General Hospital commented on presentations given at the recent event, as well as key takeaways from his own discussion on novel imaging approaches in multiple sclerosis. [WATCH TIME: 2 minutes]

The director of Cleveland Clinic’s Epilepsy Center discussed the currently known overlap between neurological diseases and the need to identify causative biomarkers. [WATCH TIME: 4 minutes]

The director of the Multiple Sclerosis and Neuromyelitis Optica Unit at Massachusetts General Hospital outlined a presentation he gave at a recent Institutional Perspectives in Neurology: MS event. [WATCH TIME: 3 minutes]

The chief medical officer at Atara Biotherapeutics provided insight on the future direction of its investigational agent ATA188 following new data that suggested a link between Epstein-Barr virus and multiple sclerosis. [WATCH TIME: 4 minutes]

The director of the Division of Neuromuscular Diseases at UC Irvine discussed the positive data, noting that the treatment was “incredibly safe.” [WATCH TIME: 4 minutes]

The assistant director of the Allegheny Headache Center explained the origins of the recently launched headache registry, which keeps data about patients’ responses to medications. [WATCH TIME: 6 minutes]

Chaired by Eric Klawiter, MD, MSc, the presentations also feature Mass General and Brigham and Women's experts Tanuja Chitnis, MD; Kristin Galetta, MD; and Michael Levy, MD, PhD. [WATCH TIME: 1 hour, 26 minutes]

The professor of neurology at Brigham and Women’s Hospital discussed her presentation on B-cell depleting therapies such as ocrelizumab and ofatumumab for the treatment of multiple sclerosis. [WATCH TIME: 2 minutes]

The Samuel W. Fordyce professor and director of Geriatric Psychiatry at the St. Louis University School of Medicine discussed the motivation behind recently published recommendations for clinicians who treat psychosis in neurodegenerative diseases in a telemedicine setting. [WATCH TIME: 4 minutes]

The chief medical officer of Prime PD, a new digital wellness studio for patients with Parkinson disease, detailed future initiatives for the platform. [WATCH TIME: 4 minutes]

Closing their discussion on insomnia, panelists share final thoughts and advice for community physicians.

Expert panelists share their excitement for novel agents that may impact the insomnia treatment landscape.

The CMO of the digital wellness studio detailed the positive feedback received thus far from patients with Parkinson disease. [WATCH TIME: 6 minutes]

Neurology News Network for the week ending February 12, 2022. [WATCH TIME: 3 minutes]

The CMO of the digital wellness studio spoke on the options to personalize training curricula for patients with Parkinson disease. [WATCH TIME: 4 minutes]

Jeffrey Cohen, MD, director, Mellen Center for MS Treatment and Research, Cleveland Clinic; and president, ACTRIMS, discussed what he is looking forward to at the 2022 ACTRIMS Forum, as well as the overarching themes of the meeting. [WATCH TIME: 2 minutes]

The chief medical officer at Atara Biotherapeutics discussed the investigational agent ATA188, its mechanism to treat multiple sclerosis, and what to look for in its upcoming EMBOLD trial data readout. [WATCH TIME: 4 minutes]

The director of Cleveland Clinic’s Epilepsy Center provided insight on a new 20-year initiative to uncover more about the origins of neurological diseases and how they occur prior to symptom onset. [WATCH TIME: 3 minutes]

The chief medical officer of Prime PD spoke on motivations behind the development of the program and the unique benefits it offers amidst the ongoing COVID-19 pandemic. [WATCH TIME: 3 minutes]

The chief medical officer at Atara Biotherapeutics detailed the clinical significance of a recently published paper in Nature that adds to the evidence that Epstein-Barr virus is the leading cause of multiple sclerosis. [WATCH TIME: 3 minutes]

Discussing data from an early safety study, the chief scientific officer of FibroBiologics commented on the benefits of a staggered approach to their clinical research in multiple sclerosis. [WATCH TIME: 5 minutes]

The chief scientific officer of FibroBiologics discussed the benefits of fibroblast cell technology for this patient population, particularly the absence of adverse effects. [WATCH TIME: 3 minutes]